Can B Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Can B Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $122.7K | Apr 6, 2018 |
| FY2017 | Dec 31, 2016 | $95.1K | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | $110.4K | Apr 10, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.16M | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $6.69M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $4.60M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.71M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.31M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $668.6K | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | $122.7K | Apr 17, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $358.7K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $2.61M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.99M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.43M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.71M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $263.1K | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | $78.3K | Apr 17, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($9.74M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($14.92M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($12.17M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($8.88M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($5.90M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($4.11M) | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | ($2.14M) | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | ($665.1K) | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | ($3.59M) | Apr 10, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($7.49M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($14.17M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($10.27M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($7.54M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($5.89M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($3.42M) | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | ($712.8K) | Apr 17, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $165.0K | Apr 14, 2021 |
| FY2020 | Dec 31, 2019 | $150.0K | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $75.0K | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | $37.0K | Apr 17, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $926.7K | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $675.3K | Apr 17, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($1.30M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($3.95M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($7.47M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.95M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($2.41M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($753.6K) | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | ($286.3K) | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | ($142.4K) | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | ($337.4K) | Apr 10, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $15.0K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $538.8K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $50.2K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.11M | Apr 14, 2021 |
| FY2018 | Dec 31, 2018 | $46.4K | Apr 17, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $10.13M | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $15.56M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $16.47M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.91M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $7.21M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $3.69M | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | $219.3K | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | $137.0K | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | $180.3K | Apr 10, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $11.13M | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $12.86M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $10.86M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.44M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $564.7K | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $204.8K | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.95M | Apr 17, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($1.00M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $2.70M | Apr 15, 2024 |
| FY2023 | Dec 31, 2021 | $5.62M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.48M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | $6.65M | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | $3.49M | Apr 14, 2021 |
| FY2019 | Dec 31, 2017 | ($1.73M) | Apr 2, 2020 |
| FY2018 | Dec 31, 2016 | ($514.6K) | Apr 17, 2019 |
| FY2017 | Dec 31, 2015 | $103.3K | Apr 6, 2018 |
| FY2016 | Dec 31, 2014 | $16.2K | Apr 10, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $55.8K | Apr 14, 2021 |
| FY2020 | Dec 31, 2019 | $55.8K | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $55.8K | Apr 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($102.43M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($92.69M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($77.77M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($65.60M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($24.67M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($18.77M) | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | ($14.65M) | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | ($12.51M) | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | ($11.84M) | Apr 10, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $34.0K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $73.2K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $449.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $457.8K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $46.5K | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $807.7K | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.7K | Apr 17, 2019 |
| FY2018 | Dec 31, 2016 | $30.2K | Apr 17, 2019 |
| FY2017 | Dec 31, 2015 | $18.4K | Apr 6, 2018 |
| FY2016 | Dec 31, 2014 | $100.5K | Apr 10, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | (4) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | (9) | Apr 17, 2023 |
| FY2020 | Dec 31, 2020 | (1) | Apr 14, 2021 |
| FY2020 | Dec 31, 2019 | (2) | Apr 14, 2021 |
| FY2016 | Dec 31, 2015 | 0 | Apr 10, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | (4) | Apr 15, 2024 |
| FY2020 | Dec 31, 2020 | (1) | Apr 14, 2021 |
| FY2020 | Dec 31, 2019 | (2) | Apr 14, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 4.42M | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | 2.83M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 2.83M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 369,639 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 2.68M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | 440.57M | Apr 2, 2020 |
| FY2018 | Dec 31, 2017 | 225.57M | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | 146.01M | Apr 6, 2018 |
| FY2016 | Dec 31, 2015 | 145.36M | Apr 10, 2017 |